' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.
Bachmayer, S; Fastner, G; Vaszi, A; Iglseder, W; Kopp, P; Holzinger, J; Dinnewitzer, A; Rinnerthaler, G; Gampenrieder, SP; Emmanuel, K; Greil, R; Sedlmayer, F; Zehentmayr, F;
Strahlenther Onkol. 2018; 194(7): 627-637.
Originalarbeiten (Zeitschrift)


Dinnewitzer Adam
Emmanuel Klaus
Fastner Gerd
Gampenrieder Simon Peter
Greil Richard
Holzinger Josef
Iglseder Wolfgang
Kopp Andrea
Rinnerthaler Gabriel
Sedlmayer Felix
Zehentmayr Franz


The role of radiotherapy (RT) for nonmetastatic pancreatic cancer is still a matter of debate since randomized control trials have shown inconsistent results. The current retrospective single-institution study includes both resected and unresected patients with nonmetastasized pancreatic cancer. The aim is to analyze overall survival (OS) after irradiation combined with induction chemotherapy.
Of the 73 patients with nonmetastatic pancreatic cancer eligible for the present analysis, 42 (58%) patients had adjuvant chemoradiotherapy (CRT), while 31 (42%) received CRT as primary treatment. In all, 65 (89%) had chemotherapy at any time before, during, or after RT, and 39 (53%) received concomitant CRT. The median total dose was 50 Gy (range 12-77 Gy), while 61 (84%) patients received >40 Gy.
With a median follow-up of 22 months (range 1.2-179.8 months), 14 (19%) are still alive and 59 (81%) of the patients have died, whereby 51 (70%) were cancer-related deaths. Median OS and the 2‑year survival rate were 22.9 months (1.2-179.8 months) and 44%, respectively. In addition, 61 (84%) patients treated with >40 Gy had a survival advantage (median OS 23.7 vs. 17.3 months, p = 0.026), as had patients with 4 months minimum of systemic treatment (median OS 27.5 vs. 14.3 months, p = 0.0004).
CRT with total doses >40 Gy after induction chemotherapy leads to improved OS in patients with nonmetastatic pancreatic cancer.

Find related publications in this database (Keywords)

Pancreatic cancer
Adjuvant chemotherapy
Overall survival
Retrospective analysis